Skip to content

Pain Expectations in Subjects With Osteoarthritis

A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02155257
Enrollment
30
Registered
2014-06-04
Start date
2014-07-31
Completion date
2017-10-31
Last updated
2019-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

Osteoarthritis, Knee pain, Hip pain, Total Knee Replacement Surgery

Brief summary

The purpose of this research study is to test whether or not researchers can alter or change expectations on pain. The researchers will test whether there is an effect on the size of the pupil and responses to thermal heat temperatures in subjects with osteoarthritis of the knee or hip or healthy subjects for comparison. One of 3 possible treatment groups will be administered to qualifying subjects: (1) gabapentin, a medication that is commonly used to treat nerve pain, (2) modafinil, a medication that is commonly used to treat people with narcolepsy (a disorder that causes people to fall asleep) and (3) a placebo, which is an inactive substance, like a sugar pill, that is not thought to have any effect on your disease or condition

Detailed description

Purpose and rationale for this study: Both chronic pain and disability after total knee replacement surgery are predicted by negative cognitive-affective state, characterized by depression, anxiety, and a cognitive style dominated by catastrophizing. How this negative state results in chronic pain and disability is not known, but we hypothesize that it causes dysfunction of the release of the neurotransmitter, norepinephrine in several regions of the brain, mid-brain, and spinal cord that are important to many processes involved in recovery from surgery. Objectives: (1) Gabapentin and modafinil will increase resting pupil diameter with a moderate effect size in patients with osteoarthritis; (2) Expectations will modify pain experience with a moderate effect size in these patients Methods: 30 subjects with moderate average daily pain from osteoarthritis of the knee or hip or healthy subjects will be recruited and will come to the clinical research unit at Wake Forest. Informed consent will be confirmed and they will complete the questionnaires. We will take a verbal medical and medication history and obtain blood pressure and heart rate measurements. Verbal pain intensity report (0-10 from no pain to worst pain imaginable) will be obtained from a 5 second heat stimuli, separated by 30 seconds, delivered to a nonpainful area of skin on the arm as described in preliminary data. During pain testing, study subjects will sit in a comfortable chair in a low-ambient light room with their head positioned on a chin rest for continuous recording of pupil diameter using a near infrared recording system as described in preliminary data. Pupil diameter and probe temperature will be passed through an analog to digital converter and acquired at 60 Hertz (Hz) for subsequent analysis. Five sequences of test stimuli will be presented, with a brief break in between each sequence. The first sequence will consist of 7 stimuli, from 39⁰ to 51⁰ Celsius (C) in 2⁰C increments, in ascending order. Data from this training sequence will not be used for analysis. Sequences 2 and 3 will consist of 5, 5-second stimuli, presented in random order, to generate moderate (50⁰C) and mild (47⁰C) pain (random condition). Sequences 4 and 5 will also consist of random presentation of 5 stimuli at these temperatures, but with different auditory tones 6 s prior to stimulus onset to correctly cue the stimulus temperature (cued condition). Subjects will then be randomized to receive oral gabapentin, 900 milligram (mg), modafinil, 200 mg, or placebo, followed 2 hours later by pain testing with pupillometry, consisting of different sequences. The random and cued paradigms will be presented twice each followed by a sequence with one miscue in the positive expectation for pain direction (signal for 50⁰C but deliver 47⁰C) and one in the negative expectation for pain direction. Subjects will provide verbal pain intensity scores after each stimulus.

Interventions

DRUGModafinil
DRUGGabapentin
DRUGPlacebo

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Osteoarthritis of the knee or hip * Adult (ages 18-80) * Moderate pain (verbal score of ≥ 4 ≤ 7 on 0-10 scale for average pain intensity with normal activity) * American Society of Anesthesiologists physical status 1-3 * Healthy subjects without pain

Exclusion criteria

* Pregnancy; * Currently taking gabapentin * Currently taking a narcotic prescription medication that is \> 50 mg morphine equivalents/day * Advanced or unstable cardiac, pulmonary, renal or hepatic dysfunction * History of previous eye surgery * Psychotic disorder or a recent psychiatric hospitalization

Design outcomes

Primary

MeasureTime frameDescription
Pain Intensity RatingReported 5 seconds after each stimulusPain is reported verbally after each stimulus by the subject on a scale of 0 (no pain) to 10 (worst imagineable pain). For each individual the value used is the average of all presentations of the 50 degree stimulus.
Resting Pupil DiameterBaseline and 2 hoursResting pupil diameter will be measured using an infrared camera to obtain baseline measurements 2 hours after dosing subject pupil diameter measurements will be repeated
Cognitive StylebaselineCognitive style determined for each individual by subtracting the score in the Pain Catastrophizing Scale (CATS) questionnaire (with a score range of 0-52 with higher score showing more catastrophizing) from the Life Orientation Test Revised (LOT-R) questionnaire (score range of 0-24, with a higher score denoting a better outcome). Thus, the total score could range from ranges from -52 to 24, with lower scores indicating worse cognitive style related to pain reporting and higher scores indicating better cognitive style related to pain reporting. There are no subscales here.

Countries

United States

Participant flow

Participants by arm

ArmCount
Modafinil
Modafinil 200 mg will be administered orally one time Modafinil
10
Placebo
A placebo will be administered orally one time Placebo
10
Gabapentin
Gabapentin 900 mg will be administered orally one time Gabapentin
10
Total30

Baseline characteristics

CharacteristicModafinilPlaceboGabapentinTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
10 Participants10 Participants10 Participants30 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
10 Participants10 Participants9 Participants29 Participants
Sex: Female, Male
Female
4 Participants7 Participants6 Participants17 Participants
Sex: Female, Male
Male
6 Participants3 Participants4 Participants13 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 100 / 10
other
Total, other adverse events
0 / 100 / 100 / 10
serious
Total, serious adverse events
0 / 100 / 100 / 10

Outcome results

Primary

Cognitive Style

Cognitive style determined for each individual by subtracting the score in the Pain Catastrophizing Scale (CATS) questionnaire (with a score range of 0-52 with higher score showing more catastrophizing) from the Life Orientation Test Revised (LOT-R) questionnaire (score range of 0-24, with a higher score denoting a better outcome). Thus, the total score could range from ranges from -52 to 24, with lower scores indicating worse cognitive style related to pain reporting and higher scores indicating better cognitive style related to pain reporting. There are no subscales here.

Time frame: baseline

ArmMeasureValue (MEAN)Dispersion
ModafinilCognitive Style18.2 score on a scaleStandard Deviation 2.3
PlaceboCognitive Style15.5 score on a scaleStandard Deviation 2.3
GabapentinCognitive Style14.8 score on a scaleStandard Deviation 5.7
Primary

Pain Intensity Rating

Pain is reported verbally after each stimulus by the subject on a scale of 0 (no pain) to 10 (worst imagineable pain). For each individual the value used is the average of all presentations of the 50 degree stimulus.

Time frame: Reported 5 seconds after each stimulus

ArmMeasureValue (MEAN)Dispersion
ModafinilPain Intensity Rating3.2 units on a scaleStandard Deviation 1.7
PlaceboPain Intensity Rating2.8 units on a scaleStandard Deviation 1.8
GabapentinPain Intensity Rating2.8 units on a scaleStandard Deviation 2
Primary

Resting Pupil Diameter

Resting pupil diameter will be measured using an infrared camera to obtain baseline measurements 2 hours after dosing subject pupil diameter measurements will be repeated

Time frame: Baseline and 2 hours

ArmMeasureGroupValue (MEAN)Dispersion
ModafinilResting Pupil DiameterBaseline64 mmStandard Deviation 11.5
ModafinilResting Pupil Diameter2 Hours66.9 mmStandard Deviation 11.9
PlaceboResting Pupil DiameterBaseline72 mmStandard Deviation 12.6
PlaceboResting Pupil Diameter2 Hours70.9 mmStandard Deviation 14.5
GabapentinResting Pupil DiameterBaseline69 mmStandard Deviation 12.7
GabapentinResting Pupil Diameter2 Hours66.1 mmStandard Deviation 13.5
Comparison: Interaction between resting pupil diameter and correlation of cognitive-affective style to pain reporting. Note that this analysis is an INTERACTION between the primary outcome of this measure (pupil diameter) to that of the primary outcome measure of cognitive-affective style.p-value: 0.5495% CI: [-0.39, 0.76]Regression, Linear

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026